Changes in acromegaly treatment over four decades in Spain: analysis of the Spanish Acromegaly Registry (REA)

被引:0
作者
Gemma Sesmilo
Sonia Gaztambide
Eva Venegas
Antonio Picó
Carlos Del Pozo
Concepción Blanco
Elena Torres
Cristina Álvarez-Escolà
Carmen Fajardo
Rogelio García
Rosa Cámara
Ignacio Bernabeu
Alfonso Soto
Carles Villabona
Alicia Serraclara
Irene Halperin
Victoria Alcázar
Elisabet Palomera
Susan M. Webb
机构
[1] Institut Universitari Dexeus,Servicio de Endocrinología
[2] Hospital de Cruces,Servicio de Endocrinología
[3] Hospital Universitario Virgen del Rocío,Servicio de Endocrinología
[4] Hospital General Universitario,Servicio de Endocrinología
[5] Hospital Mútua de Terrassa,Servicio de Endocrinología
[6] Hospital Príncipe de Asturias,Servicio de Endocrinología
[7] Hospital Universitario San Cecilio,Servicio de Endocrinología
[8] Hospital Universitario la Paz,Servicio de Endocrinología
[9] Hospital de la Ribera,Servicio de Endocrinología
[10] Hospital Gregorio Marañón,Servicio de Endocrinología
[11] Hospital La Fe,Servicio de Endocrinología
[12] Hospital Clínico Universitario de Santiago,Servicio de Endocrinología
[13] Hospital de Bellvitge,Servicio de Endocrinología
[14] Hospital 12 de Octubre,Servicio de Endocrinología
[15] Hospital Clínic,Servicio de Endocrinología
[16] Hospital Severo Ochoa,Servicio de Endocrinología
[17] Hospital de Mataró,Estadística, Unitat de Recerca
[18] Universitat Autònoma de Barcelona,IIB
来源
Pituitary | 2013年 / 16卷
关键词
Acromegaly; Registry; Treatment;
D O I
暂无
中图分类号
学科分类号
摘要
Since 1997 there is an online National Registry of acromegalic patients in Spain (REA). We aimed to study changes in acromegaly treatment and outcomes over the last four decades in Spain. In REA clinical and biochemical data are collected at diagnosis and updated every one to 2 years. We analyzed the first treatment received and the different treatments administered according to decade of diagnosis of acromegaly: prior to 1980, 1980–1989, 1990–1999 and 2000–2009. Surgical cure rates according to pretreatment with long-acting somatostatin receptor ligands (SRLs) were also analyzed. 1,658 patients were included of which 698 had accurate follow-up data. Treatment of acromegaly changed over time. Surgery was the main treatment option (83.8 %) and medical treatment was widely used (74.7 %) both maintained over decades, while radiation therapy declined (62.8, 61.6, 42.2 and 11.9 % over decades, p < 0.001). First treatment type also changed: surgery was the first line option up until the last decade in which medical treatment was preferred (p < 0.001). Radiotherapy was barely used as first treatment. Treatment combinations changed over time (p < 0.001). The most common treatment combination (surgery plus medical therapy), was received by 24.4, 16.4, 25.3 and 56.5 % of patients over decades. Medical treatment alone was performed in 7.3, 6, 7.2 and 14.7 % over decades. Type of medical treatment also changed, SRLs becoming the first medical treatment modality in the last decades, whereas dopamine agonist use declined (p < 0.001). Surgical cure rates improved over decades (21, 21, 36 and 38 %, p = 0.002) and were not influenced by SRL pre-surgical use. Acromegaly treatment has changed in Spain in the last four decades. Surgery has been the main treatment option for decades; however, medical therapy has replaced surgery as first line in the last decade and radiotherapy rates have clearly declined. SRLs are the most used medical treatment.
引用
收藏
页码:115 / 121
页数:6
相关论文
共 214 条
[1]  
Etxabe J(1993)Acromegaly: an epidemiological study J Endocrinol Invest 16 181-187
[2]  
Gaztambide S(2004)Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish Acromegaly Registry (Registro Espanol de Acromegalia, REA) Eur J Endocrinol 151 439-446
[3]  
Latorre P(2009)Guidelines for acromegaly management: an Update J Clin Endocrinol Metab 94 1509-1517
[4]  
Vazquez JA(2000)Davis RJ.T reatment of acromegaly with the growth hormone-receptor antagonist pegvisomant N Engl J Med 342 1171-1177
[5]  
Mestron A(1994)Pharmacokinetics and efficacy of the long-acting somatostatin analogue somatuline in acromegaly Eur J Endocrinol 130 229-234
[6]  
Webb SM(1999)Comparison of monthly intramuscular injections of Sandostatin LAR with multiple subcutaneous injections of octreotide in the treatment of acromegaly; effects on growth hormone and other markers of growth hormone secretion Clin Endocrinol 50 245-251
[7]  
Astorga R(2004)One-year follow-up of patients with acromegaly treated with fixed or titrated doses of lanreotide Autogel Clin Endocrinol 60 734-740
[8]  
Benito P(2006)Efficacy of lanreotide Autogel administered every 4–8 weeks in patients with acromegaly previously responsive to lanreotide microparticles 30 mg: a phase III trial Clin Endocrinol (Oxf) 65 320-326
[9]  
Catala M(2011)Efficacy and acceptability of lanreotide Autogel Exp Clin Endocrinol Diabetes 119 156-162
[10]  
Gaztambide S(2003) 120 mg at different dose intervals in patients with acromegaly previously treated with octreotide LAR Clin Endocrinol (Oxf) 58 288-295